Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

October 20, 2005 09:11 ET

Swiss Medica's Unique O24 Fibromyalgia Is Now Available In Over 5,000 Retail Stores And Expects It To Be Sold In More Than 10,000 Stores Before Year-End

TORONTO, ONTARIO--(CCNMatthews - Oct. 20, 2005) - Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that over 5,000 retail stores are now selling O24 Fibromyalgia™ throughout the United States. In addition, the Company expects O24 Fibromyalgia™ to be available in more than 10,000 stores before year-end. O24 Fibromyalgia™ is the only over-the-counter or prescription product, that has been clinically shown to relieve fibromyalgia pain and carries the National Fibromyalgia Association's coveted "seal of approval". Up to 11-million Americans who suffer from fibromyalgia now have a solution for their pain. For detailed store availability, please see the store locator at www.024zone.com/Retailers.html

What is Fibromyalgia?

Fibromyalgia (FM) is an increasingly recognized chronic pain illness which is characterized by widespread musculoskeletal aches, pain and stiffness, soft tissue tenderness, general fatigue and sleep disturbances. The most common sites of pain include the neck, back, shoulders, pelvic girdle and hands, but any body part can be involved. Fibromyalgia patients experience a range of symptoms of varying intensities that wax and wane over time. According to the National Fibromyalgia Association, it is estimated that approximately 3-6% of the U.S. population has FM. Although a higher percentage of women are affected, it does strike men, women and children of all ages and races. Because of its debilitating nature, Fibromyalgia has a serious impact on patients' family, friends, and employers, as well as society at large.

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica is launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit www.024zone.com for information on O24 Fibromyalgia and to order the product online.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.


Contact Information

  • Swiss Medica, Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    or
    Fusion Communications
    Public Relations Contact:
    Dean Mailey
    (604) 218-6767
    dean@fusioncom.ca
    or
    Stern & Co.
    Financial Media Contact: Stan Froelich
    VP, Media Relations
    (212) 888-0044
    sfroelich@sternco.com